Abstract: The present invention relates to a protective peptide or a functionally active variant of the protective peptide; a composition comprising at least two proteins selected from the group consisting of i) a first type of protective peptide or functionally active variant thereof, ii) a second type of protective peptide or functionally active variant thereof and iii) a supportive peptide or a functionally active variant thereof; one or more nucleic acid(s) encoding the protective peptide or functionally active variant thereof or the at least two proteins comprised in the composition; a pharmaceutical composition comprising the protective peptide or functionally active variant thereof, the composition, or the nucleic acid(s); a method of producing an antibody using the protective peptide or functionally active variant thereof or the composition; the use of the protective peptide or functionally active variant thereof and/or the composition and/or the nucleic acid(s) for the manufacture of a medicament for the immun

Abstract: Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes, methods for isolating such antigens and specific uses therefore.

Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pneumoniae, methods for isolating such antigens and specific uses thereof.

Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. epidermidis, methods for isolating such antigens and specific uses thereof.

Abstract: The invention relates to a method for preventing or treating Hepatitis C Virus (HCVi) infections, wherein a HCV vaccine comprising an effective amount of at least one HCV T-cell antigen and a polycationic compound comprising peptide bonds is administered to a human individual bi-weekly at least 3 times.

Abstract: The present invention provides novel adjuvant systems for the potentiation of immune responses against antigenic targets.

Abstract: The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.

Abstract: The invention discloses the use of polycationic compounds for the preparation and manufacturing of medicaments, pharmaceutical compositions, especially vaccines for the treatment of patients with HCV chronic infections.

Abstract: The present invention is related to nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and uses thereof. More particularly, the present invention is related to a polypeptide being such adhesion factors and comprising an amino acid sequence, whereby the amino acid sequence is selected from the group comprising SEQ ID NO 11 to SEQ ID NO 20, and the use of such polypeptide for the manufacture of a vaccine.

Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, methods for isolating such antigens and specific uses thereof.

Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.

Abstract: Described is a vaccine which comprises at least one antigen and at least one cathelicidin derived antimicrobial peptide or a derivative thereof as well as the use of a cathelicidin derived antimicrobial peptide or a derivative thereof for the preparation of an adjuvant for enhancing the immune response to at least one antigen.

Abstract: Described is a method for making a pharmaceutical preparation comprising the solubilisation of a peptide mixture, characterized in that the peptide mixture is solubilized by an aqueous solution containing at least one organic acid selected from the group consisting of formic acid, acetic acid, propionic acid, butyric acid and halogenated or hydroxylated forms thereof.

Abstract: Described is a method for isolating Hepatitis C Virus peptides (HPs) which have a binding capacity to a MHC/HLA molecule or a complex comprising said HCV-peptide and said MHC/HLA molecule characterized by the following steps: —providing a pool of HCV-peptide, said pool containing HCV-peptides which bind to said MHC/HLA molecule and HCV-peptides which do not bind to said MHC/HLA molecule, —contacting said MHC/HLA molecule with said pool of HCV-peptides whereby a HCV-peptide which has a binding capacity to said MHC/HLA molecule binds to said MHC/HLA molecule and a complex comprising said HCV-peptide and said MHC/HLA molecule is formed, —detecting and optionally separating said complex from the HCV-peptide which do not bind to said MHC/HLA molecule and optionally isolating and characterizing the HCV-peptide from said complex.

Abstract: The invention relates to a modified VP1-capsid protein of parvovirus B19 having a reduced phospholipase A2-like enzyme activity as compared to the wild type VP1-capsid protein of parvovirus B19 having the amino acid sequence of SeqID 1.

Abstract: The invention relates to a composition comprising a T cell epitope or a mixture of T cell epitopes a polycationic peptide and a nucleic acid based on inosin and cytosin and its use as a vaccine.

Abstract: The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

Abstract: The invention discloses polypeptides encoded by an alternative reading frame of a pathogenic virus, which polypeptides—start with a methionine amino acid residue,—comprise an antigenic determinant and—comprise more than 7 amino acid residues and fragments of said polypeptides comprising more than 7 amino acids.

Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from enteroaggregative E. coli, enterotexigenic E. coli, S. flexneri and C. jejuni, methods for isolating such antigens and specific uses thereof.